title: A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals.
abstract: Extended and continuous infusions with beta-lactam antibiotics have been suggested as a means of pharmacokinetic and pharmacodynamic optimisation of antimicrobial therapy. Vancomycin is also frequently administered in continuous infusion, although more for practical reasons. A survey was undertaken to investigate the recommendations by the local antibiotic management teams (AMTs) in Belgian acute hospitals concerning the administration (intermittent, extended or continuous infusion) and therapeutic drug monitoring of four beta-lactam antibiotics (ceftazidime, cefepime, piperacillin-tazobactam, meropenem) and vancomycin for adult patients with a normal kidney function. A structured questionnaire survey comprising three domains was developed and approved by the members of the Belgian Antibiotic Policy Coordination Committee (BAPCOC). The questionnaire was sent by e-mail to the official AMT correspondents of 105 Belgian hospitals, followed by two reminders. The response rate was 32 %, with 94 %, 59 %, 100 %, 100 % and 100 % of the participating Belgian hospitals using ceftazidime, cefepime, piperacillin-tazobactam, meropenem and vancomycin, respectively. Comparing intensive care unit (ICU) with non-ICU wards showed a higher implementation of extended or continuous infusions for ceftazidime (81 % vs. 41 %), cefepime (35 % vs. 10 %), piperacillin-tazobactam (38 % vs. 12 %), meropenem (68 % vs. 35 %) and vancomycin (79 % vs. 44 %) on the ICU wards. A majority of the hospitals recommended a loading dose prior to the first dose. For vancomycin, the loading dose and the trough target concentration were too low based on the current literature. This survey shows that extended and continuous infusions with beta-lactams and vancomycin are widely implemented in Belgian hospitals.
authors.affiliation: Pharmacy Department, Ghent University Hospital, De Pintelaan, 185, 9000, Ghent, Belgium. franky.buyle@uzgent.be
authors.forename: F M
authors.initials: FM
authors.lastname: Buyle
authors.forename: J
authors.initials: J
authors.lastname: Decruyenaere
authors.forename: J
authors.initials: J
authors.lastname: De Waele
authors.forename: P M
authors.initials: PM
authors.lastname: Tulkens
authors.forename: T
authors.initials: T
authors.lastname: Van Audenrode
authors.forename: P
authors.initials: P
authors.lastname: Depuydt
authors.forename: G
authors.initials: G
authors.lastname: Claeys
authors.forename: H
authors.initials: H
authors.lastname: Robays
authors.forename: D
authors.initials: D
authors.lastname: Vogelaers
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001530:Belgium; D019538:Health Care Surveys; D006761:Hospitals; D006801:Humans; D007362:Intensive Care Units; D010362:Patients' Rooms; D011795:Surveys and Questionnaires; D014640:Vancomycin / Q000008:administration & dosage*; D047090:beta-Lactams / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D014640:Vancomycin